Since FDA approved first siRNA-based drug (patisiran) for polyneuropathy treatment, doors have been opened to utilize siRNA as a therapeutic agent for treatment of various diseases. Recently, FDA approved second siRNA drug (Givlaari) for rare disease. Moreover, there are at least 30 siRNA-based drugs in clinical trials process for several pathological conditions such as viral infections, cancer, genetic disorders, neurological disorders and autoimmune disorders. This demonstrates the significant potential of these therapeutic strategies, which promise to be effective in a wide range of currently untreatable disorders. miRNA-based drugs https://integraterna.creative-biogene.com/application/mirna-based-drugs.html